VISEN Pharmaceuticals operates as a biopharmaceutical company. The company is headquartered in Suzhou, Jiangsu and currently employs 54 full-time employees. The company went IPO on 2025-03-21. The firm's main products under development include lonapegsomatropin, navepegritide, and palopegteriparatide. The lonapegsomatropin is used to treat growth hormone deficiency in children aged 3 to 17 years old. The navepegritide is a disease repair therapy used to treat children with cartilage dysplasia aged 2 to 10 years old. The palopegteriparatide is a treatment method used to treat adult hypoparathyroidism. The firm is in the late stage of research and development, and its products are close to commercialization.
02561.HK stock price ended at $34 on 星期一, after rising 0.59%
On the latest trading day Jan 19, 2026, the stock price of 02561.HK rose by 0.59%, climbing from $33.30 to $34.00. Throughout the session, the stock experienced a volatility of 4.38%, with prices fluctuating between a daily low of $33.30 and a high of $34.76. Alongside this price increase, trading volume also rose by 14.7K shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, 900 shares were traded, amounting to a market value of approximately $3.8B.